# A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

> **NCT04911881** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IBI321

## Key facts

- **NCT ID:** NCT04911881
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-24
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911881, "A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT04911881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*